Core Viewpoint - Company ST Jingfeng has received a court ruling accepting a restructuring application from creditors, indicating potential financial distress and the initiation of a formal restructuring process [1] Group 1: Legal Proceedings - The Changde Intermediate People's Court in Hunan Province has accepted the restructuring application for the company [1] - Beijing Zhonglun Law Firm has been appointed as the administrator for the company's restructuring [1] Group 2: Stock Market Impact - According to the Shenzhen Stock Exchange listing rules, the company's stock will be subject to delisting risk warning starting from October 23, 2025, with the stock name changing to "*ST Jingfeng" [1] - The stock code will remain "000908," and the daily price fluctuation limit will continue to be 5% [1] - The company's stock will be suspended for trading on October 22, 2025, and will resume trading on October 23, 2025 [1]

Core Viewpoint - ST Jingfeng (000908) announced that the Changde Intermediate People's Court has accepted the creditors' application for the company's reorganization, leading to a risk warning for the company's stock, which will be renamed "*ST Jingfeng" starting October 23 [1] Summary by Relevant Sections - **Stock Trading and Suspension** - The company's stock will be subject to a delisting risk warning effective October 23, with a new trading name "*ST Jingfeng" [1] - The stock will be suspended from trading on October 22 and will resume trading on October 23 [1] - **Market Regulations** - The daily price fluctuation limit for the stock remains at 5% [1]

证券代码：000908 证券简称：ST景峰 公告编号：2025-075 湖南景峰医药股份有限公司 关于法院裁定受理公司重整并指定管理人及公司股票交易 将被实施退市风险警示暨公司股票停复牌并变更证券简称 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、2025 年 10 月 21 日，湖南景峰医药股份有限公司（以下简称"公司"或"景 峰医药"）收到湖南省常德市中级人民法院（以下简称"常德中院"或"法院"） 送达的（2024）湘 07 破申 7 号《民事裁定书》，常德中院裁定受理债权人对公司的 重整申请。同日，公司收到常德中院送达的（2025）湘 07 破 15 号《决定书》，常 德中院指定北京市中伦律师事务所担任公司管理人。 2、由于公司最近三个会计年度扣除非经常性损益前后净利润孰低者均为负值， 且最近一年审计报告显示公司持续经营能力存在不确定性，公司股票被实施其他风 险警示，具体内容详见公司于 2025 年 6 月 13 日在巨潮资讯网披露的《关于撤销退 市风险警示及部分其他风险警示暨继续被实施其他风险警示暨公司股票停复牌的公 告》（公 ...

Core Viewpoint - ST Jinfeng (000908.SZ) has received a court ruling from Changde Intermediate Court accepting the creditors' restructuring application, indicating significant financial distress and potential operational changes for the company [1] Group 1: Court Ruling and Restructuring - The Changde Intermediate Court has accepted the creditors' restructuring application for ST Jinfeng, appointing Beijing Zhonglun Law Firm as the administrator [1] - The court's decision is documented in the civil ruling (2024) Xiang 07 Po Shen 7 and the decision (2025) Xiang 07 Po 15 [1] Group 2: Stock Market Implications - Following the court's ruling, ST Jinfeng's stock will be subject to delisting risk warning, effective from October 23, 2025, with the stock name changing to "*ST Jinfeng" while the security code remains "000908" [1] - The daily price fluctuation limit for the stock will continue to be set at 5% [1] - The stock will be suspended from trading on October 22, 2025, and will resume trading on October 23, 2025 [1]

Core Viewpoint - ST Jinfeng (000908.SZ) has received a court ruling accepting creditors' restructuring application, leading to significant changes in its stock trading status [1] Group 1: Court Ruling and Restructuring - The Changde Intermediate People's Court has accepted the creditors' restructuring application for the company [1] - Beijing Zhonglun Law Firm has been appointed as the administrator for the company's restructuring process [1] Group 2: Stock Trading Implications - As a result of the court ruling, the company's stock will be subject to delisting risk warning starting from October 23, 2025, with the stock name changing to "*ST Jinfeng" [1] - The stock code will remain "000908," and the daily price fluctuation limit will still be set at 5% [1] - The company's stock will be suspended from trading for one day on October 22, 2025, and will resume trading on October 23, 2025 [1]

ST景峰(000908.SZ)公告称，公司于2025年10月21日收到湖南省常德市中级人民法院送达的（2024）湘 07破申7号《民事裁定书》及（2025）湘07破15号《决定书》，常德中院裁定受理债权人对公司的重整 申请，并指定北京市中伦律师事务所担任公司管理人。根据《深圳证券交易所股票上市规则》，公司股 票交易将于2025年10月23日被实施退市风险警示，股票简称变更为"*ST景峰"，证券代码仍 为"000908"，股票日涨跌幅限制仍为5%。公司股票将于2025年10月22日开市起停牌一天，自2025年10 月23日开市起复牌。 ...

债券代码：112468 债券简称：16景峰01 摩根士丹利证券（中国）有限公司 关于湖南景峰医药股份有限公司 2016 年面向合格投资者公开发行公司债券 （第一期） 受托管理事务临时报告 债券受托管理人 （注册地址：中国（上海）自由贸易试验区世纪大道 100 号上海环球金融中心 75 楼 75T30 室） 2025 年 10 月 1 重要声明 摩根士丹利证券（中国）有限公司（以下简称"摩根士丹利证券"）编制本 报告的内容及信息均来源于湖南景峰医药股份有限公司（以下简称"景峰医药"、 "公司"、"发行人"）对外披露的公告及相关公开信息披露文件。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜作出独立判断，而不应将本报告中的任何内容据以作为摩根士丹利证券所作 的承诺或声明。在任何情况下，未经摩根士丹利证券书面许可，不得用作其他任 何用途，投资者依据本报告所进行的任何作为或不作为，摩根士丹利证券不承担 任何责任。 2 摩根士丹利证券作为湖南景峰医药股份有限公司2016年面向合格投资者公 开发行公司债券（第一期）（以下简称"16景峰01"或"本期债券"）的受托管 理人，持续密切关注对该等债券 ...

Group 1 - The ST sector index rose by 0.63%, ranking fifth among concept sectors, with 84 stocks increasing in value [2] - Notable gainers included *ST Aowei, *ST Wanfang, and ST Jingfeng, which hit the daily limit, while ST Meichen, *ST Xinyan, and *ST Yazhen saw significant increases of 10.76%, 6.23%, and 4.85% respectively [2][3] - The largest declines were observed in *ST Mubang, *ST Yuancheng, and *ST Xinchao, with decreases of 4.96%, 4.93%, and 4.19% respectively [2] Group 2 - The ST sector experienced a net outflow of 157 million yuan from major funds, with 68 stocks receiving net inflows [3] - ST Jingfeng led the net inflow with 24.43 million yuan, followed by ST Chuangyi, ST Huawen, and ST Yingfituo with net inflows of 24.20 million yuan, 19.62 million yuan, and 18.78 million yuan respectively [3][4] - The highest net inflow ratios were recorded for ST Bailing, *ST Dongyi, and ST Xinhua Jin, with rates of 84.08%, 77.54%, and 57.64% respectively [4] Group 3 - The top gainers in the ST sector included ST Jingfeng with a 5.06% increase and a turnover rate of 22.19%, alongside ST Chuangyi and ST Huawen with increases of 4.76% and 2.51% respectively [5] - Other notable gainers included *ST Yatai, *ST Fanli, and ST Lingnan, with increases of 7.20%, 3.53%, and 5.84% respectively [5] - Conversely, *ST Mubang and *ST Yuancheng saw significant declines of 4.96% and 4.93% respectively, indicating volatility within the sector [6][7]

债券代码：112468 债券简称：16景峰01 摩根士丹利证券（中国）有限公司 关于 湖南景峰医药股份有限公司 2016 年面向合格投资者公开发行公司债券 （第一期） 受托管理事务临时报告 债券受托管理人 （注册地址：中国（上海）自由贸易试验区世纪大道 100 号上海环球金融中心 75 楼 75T30 室） 2016年10月27日，公司在深圳证券交易所发行了"16景峰01"，发行金额8.00 亿元，期限3+1+1年，到期日为2021年10月27日。"16景峰01"债券存续期前3年 票面利率为3.78%，第3年末景峰医药选择上调债券票面利率至7.50%，第4年末景 峰医药选择不上调票面利率，即"16景峰01"债券在存续期第5年的票面利率为 7.50%。 1 重要声明 摩根士丹利证券（中国）有限公司（以下简称"摩根士丹利证券"）编制本 报告的内容及信息均来源于湖南景峰医药股份有限公司（以下简称"景峰医药"、 "公司"、"发行人"）对外披露的公告及相关公开信息披露文件。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜作出独立判断，而不应将本报告中的任何内容据以作为摩根士丹利证券所作 的承诺 ...

债券代码：112468 债券简称：16景峰01 摩根士丹利证券（中国）有限公司 关于 湖南景峰医药股份有限公司 2016 年面向合格投资者公开发行公司债券 （第一期） 债券受托管理人 （注册地址：中国（上海）自由贸易试验区世纪大道 100 号上海环球金融中心 75 楼 75T30 室） 2025 年 10 月 1 重要声明 摩根士丹利证券（中国）有限公司（以下简称"摩根士丹利证券"）编制本 报告的内容及信息均来源于湖南景峰医药股份有限公司（以下简称"景峰医药"、 "公司"、"发行人"）对外披露的公告及相关公开信息披露文件。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜作出独立判断，而不应将本报告中的任何内容据以作为摩根士丹利证券所作 的承诺或声明。在任何情况下，未经摩根士丹利证券书面许可，不得用作其他任 何用途，投资者依据本报告所进行的任何作为或不作为，摩根士丹利证券不承担 任何责任。 2 摩根士丹利证券作为湖南景峰医药股份有限公司2016年面向合格投资者公 开发行公司债券（第一期）（以下简称"16景峰01"或"本期债券"）的受托管 理人，持续密切关注对该等债券持有人权益有重大影响 ...